SYS6020
Phase 1Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.SYS6020 is one of 75 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
74
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
134 competitors in Systemic Lupus Erythematosus
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Medrol
PfizerPhase 3
Rinvoq
AbbViePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Gazyva
RochePhase 3
Sotyktu
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Ianalumab
NovartisPhase 3
Fludara
SanofiPhase 2
Glucocorticoid
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYS6020. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details